201 related articles for article (PubMed ID: 32652013)
21. Issues in interpreting the in vivo activity of Aurora-A.
Shagisultanova E; Dunbrack RL; Golemis EA
Expert Opin Ther Targets; 2015 Feb; 19(2):187-200. PubMed ID: 25384454
[TBL] [Abstract][Full Text] [Related]
22. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
23. Natural anthraquinone compound emodin as a novel inhibitor of aurora A kinase: A pilot study.
Wu FL; Chu PY; Chen GY; Wang K; Hsu WY; Ahmed A; Ma WL; Cheng WC; Wu YC; Yang JC
Chem Biol Drug Des; 2022 Jan; 99(1):126-135. PubMed ID: 34411446
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of mitotic interaction between the nucleoporin Tpr and aurora kinase A.
Kobayashi A; Hashizume C; Dowaki T; Wong RW
Cell Cycle; 2015; 14(9):1447-58. PubMed ID: 25789545
[TBL] [Abstract][Full Text] [Related]
25. Aurora Kinase A is critical for the Nkx6.1 mediated β-cell proliferation pathway.
Hobson A; Draney C; Stratford A; Becker TC; Lu D; Arlotto M; Tessem JS
Islets; 2015; 7(1):e1027854. PubMed ID: 26030060
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
27. Plasmid replication initiator interactions with origin 13-mers and polymerase subunits contribute to strand-specific replisome assembly.
Wawrzycka A; Gross M; Wasaznik A; Konieczny I
Proc Natl Acad Sci U S A; 2015 Aug; 112(31):E4188-96. PubMed ID: 26195759
[TBL] [Abstract][Full Text] [Related]
28. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
29. Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation.
Shi C; Tao S; Ren G; Yang EJ; Shu X; Mou PK; Liu Y; Dang Y; Xu X; Shim JS
Oncogene; 2022 May; 41(19):2734-2748. PubMed ID: 35393542
[TBL] [Abstract][Full Text] [Related]
30. Nuclear PGK1 Alleviates ADP-Dependent Inhibition of CDC7 to Promote DNA Replication.
Li X; Qian X; Jiang H; Xia Y; Zheng Y; Li J; Huang BJ; Fang J; Qian CN; Jiang T; Zeng YX; Lu Z
Mol Cell; 2018 Nov; 72(4):650-660.e8. PubMed ID: 30392930
[TBL] [Abstract][Full Text] [Related]
31. Eukaryotic DNA replication: Orchestrated action of multi-subunit protein complexes.
Kang S; Kang MS; Ryu E; Myung K
Mutat Res; 2018 May; 809():58-69. PubMed ID: 28501329
[TBL] [Abstract][Full Text] [Related]
32. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
[TBL] [Abstract][Full Text] [Related]
33. Phosphatase 1 Nuclear Targeting Subunit (PNUTS) Regulates Aurora Kinases and Mitotic Progression.
Wang F; Wang L; Fisher LA; Li C; Wang W; Peng A
Mol Cancer Res; 2019 Jan; 17(1):10-19. PubMed ID: 30190438
[TBL] [Abstract][Full Text] [Related]
34. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
35. AURORA KINASE A and related downstream molecules: A potential network for cancer therapy.
Fatma H; Siddique HR
Adv Protein Chem Struct Biol; 2023; 134():115-145. PubMed ID: 36858732
[TBL] [Abstract][Full Text] [Related]
36. Stathmin and microtubules regulate mitotic entry in HeLa cells by controlling activation of both Aurora kinase A and Plk1.
Silva VC; Cassimeris L
Mol Biol Cell; 2013 Dec; 24(24):3819-31. PubMed ID: 24152729
[TBL] [Abstract][Full Text] [Related]
37. Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells.
Zhong N; Shi S; Wang H; Wu G; Wang Y; Ma Q; Wang H; Liu Y; Wang J
Int J Oncol; 2016 Sep; 49(3):1028-38. PubMed ID: 27571708
[TBL] [Abstract][Full Text] [Related]
38. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.
Marxer M; Ma HT; Man WY; Poon RY
Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083
[TBL] [Abstract][Full Text] [Related]
39. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
40. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
Huggett MT; Tudzarova S; Proctor I; Loddo M; Keane MG; Stoeber K; Williams GH; Pereira SP
Oncotarget; 2016 Apr; 7(14):18495-507. PubMed ID: 26921250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
